Intermittent BRAF-inhibitor therapy is a feasible option: report of a patient with metastatic melanoma
Funding sources: none.
Conflicts of interest: R.G., A.H. and M.A. have served as consultants and received speakers' honoraria and meeting support from Roche and GlaxoSmithKline. I.S. received speakers' honoraria and travel support from Roche. A.K. received travel support from Roche.
No abstract is available for this article.